New hives drug faces off against market leader in major trial
NCT ID NCT06365879
First seen Nov 19, 2025 · Last updated May 20, 2026 · Updated 24 times
Summary
This study tests a new drug, omalizumab α, against the approved drug Xolair for people with chronic hives that don't get better with antihistamines. About 392 adults aged 15 to 75 will receive either drug for 12 weeks to see how well it reduces itching and hives. The goal is to find out if the new drug works as well and is as safe as the current treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huashan Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.